🇺🇸 FDA
Patent

US 11191758

Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors

granted A61KA61K31/135A61K31/428

Quick answer

US patent 11191758 (Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors) held by Uniwersytet Jagiellonski Collegium Medicum expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Uniwersytet Jagiellonski Collegium Medicum
Grant date
Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/135, A61K31/428, A61K31/435, A61K31/4418